Pharmacokinetic and pharmacodynamic analysis of platinum after combined treatment of cisplatin and procainamide hydrochloride in mice bearing P388 leukemia

Maria O. Vannozzi, Massimo Ottone, Maria A. Mariggiò, Sergio Cafaggi, Brunella Parodi, Michele Cilli, Edward Lindup, Maurizio Viale

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Our previous studies showed that procainamide hydrochloride may be an important modulator of cisplatin toxicity and antitumour activity. This study was performed in order to investigate if procainamide hydrochloride may influence the therapeutic index of cisplatin by inducing modifications of its pharmacokinetics and pharmacodymanics in vivo. Materials and Methods: The pharmacokinetic profile of cisplatin administered either in the presence or absence of procainamide hydrochloride was investigated in BDF1 female mice bearing 6-day P388 leukemia. Procainamide hydrochloride was administered i.v. at the dose of 50 mg/kg, immediately before cisplatin which, in turn, was administered i.p. at the dose of 8 mg/kg. Results: The combined administration of the antiarrhythmic drag and cisplatin caused significant differences in the pharmacokinetic profiles of Pt in plasma, ascites fluid and tissues. Filterable Pt was significantly increased both in plasma and ascites fluid in animals given the combined treatment. Similarly, a small increase was also found for total plasma Pt. These differences caused some changes of the pharmacokinetic parameters of filterable (plasma: AUC0-1h = +16%, t1/2α = +29%, t1/2b = +14%, K2p = -32%; ascites fluid: AUC0-1h = +23%, t1/2α = +78%, t1/2β = -49%, and total Pt (plasma: AUC0-1h = +19%, t1/2α = +27%, t1/2β = -22%; ascites fluid: AUC0.1h = +6%, AUCO-∞ = +43% t1/2α = +30%). The analysis of tissue Pt content showed the general increase of Pt concentration in the main organs of animals treated with cisplatin and procainamide hydrochloride, with AUC0-24h increased by 95%, 22%, 90% and 28% in kidney, liver, spleen and lung, respectively. The analysis of binding of Pt to DNA and percent interstrand cross-links (%ISCL) in P388 tumour cells showed that the % ISCL (10.44 ± 3.81% vs. 3.51 ± 0.01%) and the efficiency of ISCL formation (0.51 ± 0.14 vs. 0.17 ± 0.02% ISCL μg DNA/pg Pt) were significantly greater when cisplatin was administered in association with procainamide hydrochloride. Conclusion: Our results show that procainamide hydrochloride may alter the pharmacodynamics and the pharmacokinetics and distribution of Pt in tumored mice treated with cisplatin.

Original languageEnglish
Pages (from-to)1509-1516
Number of pages8
JournalAnticancer Research
Volume23
Issue number2 B
Publication statusPublished - Mar 2003

Keywords

  • Cisplatin
  • Pharmacokinetics and pharmacodynamics
  • Procainamide hydrochloride

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'Pharmacokinetic and pharmacodynamic analysis of platinum after combined treatment of cisplatin and procainamide hydrochloride in mice bearing P388 leukemia'. Together they form a unique fingerprint.

Cite this